Screening for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes patients using the fibrosis-4 score in medina-retrospective study

Background

Type 2 diabetes mellitus (T2DM) is a global health problem closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis. The fibrosis-4 (FIB-4) index is a standard noninvasive tool for estimating fibrosis risk. This study aimed to describe the demographics, metabolic parameters, comorbidities, and T2DM duration of patients in Medina and to screen for MASLD using the FIB-4 score.